WHO: Not recommended Remdesivir for COVID-19 treatment
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
WHO: Not recommended Remdesivir for COVID-19 treatment.
On November 20, The World Health Organization issued a statement on the 20th, saying that no matter how severe the condition of hospitalized patients with the COVID-19 is, the antiviral drug remdesivir is not recommended for treatment, because there is no evidence to show that The drug can improve the survival rate of patients or reduce the patient’s need for ventilators.
The statement said that a WHO guideline development team composed of international experts published an article in the British Medical Journal on the 20th, stating that Redecive is increasingly being used to treat patients with COVID-19 disease, but it is in clinical practice. The role in this is still unclear.
The expert group reached the above conclusion after evaluating and comparing the efficacy of several COVID-19 drugs. The evaluation covered 4 international randomized trials involving data on more than 7,000 hospitalized patients with COVID-19.
The expert group pointed out that although remdesivir cannot be determined to be completely useless so far, existing data cannot prove that the drug can significantly improve the treatment effect of patients.
Considering that Redecivir may have serious side effects and its high cost and resource consumption, the expert group decided not to recommend the drug, but at the same time it also supports the continued evaluation of Redecivir, with a view to using it for specific patient groups. The medicine provides conclusive evidence.
Remdesivir is an antiviral drug developed by Gilead Technology, USA, originally used to treat diseases such as Ebola hemorrhagic fever and Middle East respiratory syndrome.
The U.S. Food and Drug Administration approved remdesivir in October for the inpatient treatment of adult patients with COVID-19s and children over 12 years of age and weighing more than 40 kg, making it the first drug approved by the US Drug Administration for the treatment of COVID-19s .
(source:internet, reference only)